

# Spring Meeting

May 23-24, 2019

13.00 to 17.50 | 8.30 to 13.00

www.icvr-initiative.org

Hotel: Mercure Bordeaux Cite Mondial Centre  
Ville, 18 Parvis des Chartrons, 33080 Bordeaux



## Chairs:

Maarit Venermo  
Jack Cronenwett  
Art Sedrakyan

**Venue:** Service de Chirurgie Vasculaire,  
5th floor, Tripode Building, CHU Pellegrin, Place Amélie,  
Raba-Léon, 33000, Bordeaux, Fra

WED: Mama Shelter (19 Rue Poquelin Molière, 33000 Bordeaux)

## Thursday (May 23) Dinner

THU: Comptoir Cuisine (2 Place de la Comédie, 33000 Bordeaux)

11.30 to 12.00

Visit of the Bordeaux Vascular Surgery Dept. (starts at the Venue)

13.00 to 13.15

Welcome and Introductions

(Maarit Venermo, Jack Cronenwett, Art Sedrakyan)

13.15 to 15.15 Update of Current AAA Projects

Threshold for ideal center volume (Salvatore Scali, Kevin Mani, Adam Beck)

Variation in outcomes by country (Jon Boyle)

EVAR Device outcomes in rAAA (Kevin Mani, Adam Beck)

5-year survival after elective EVAR vs. open AAA repair (Nikolaj Eldrup)

15.15 to 15.45

Coffee break

15.45 to 16.45 Update on Current PAD Projects (Christian Behrendt)

Global variation in PAD treatment (Christian Behrendt, Daniel Bertges)

Suggestion and discussion of a new project:

Drug-coated/Eluting technology, possible ICVR registry and  
administrative data project with regulatory impact (Art Sedrakyan)

16.45 to 17.50

Discussion

16.45 to 17.50

Adjourn

## Friday (May 24)

08.30 to 09.30

EU MDR Update and Discussion (Tomoko Urakawa Disaro)

Project Details Presentation (Kevin Mani, Adam Beck)

09.30 to 10.30 Update of Current Carotid Projects

Delay-outcome of CEAs and CASs (Maarit Venermo, Grace Wang)

Carotid patch type and outcome (Jens Eldrup-Jorgensen)

10.30 to 11.30 ICVR Quality Improvement Initiative

Post-treatment antiplatelet and statin medication prescription

for patients undergoing arterial treatment (Adam Beck, Jialin Mao)

11.30 to 12.00

HIVE for data sharing (Art Sedrakyan, Christian Behrendt)

12.00 to 13.00

Discussion and New Ideas

Specific device outcome analyses in EVAR: FDA request possibly  
of major interest to international regulators as well

13.00

Adjourn